Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation

British Journal of Haematology

Volumn 129, Issue 3, 2005, Pages 381-391

  Mielcarek, Marco ^a,b   Burroughs, Lauri ^a,b   Leisenring, Wendy ^a,b   Diaconescu, Razvan ^a   Martin, Paul J ^a,b   Sandmaier, Brenda M ^a,b   Maloney, David G ^a,b   Maris, Michael B ^a,b   Chauncey, Thomas R ^a,b,c   Shizuru, Judith A ^d   Blume, Karl G ^d   Hegenbart, Ute ^e   Niederwieser, Dietger ^e   Forman, Stephen ^f   Bruno, Benedetto ^g   Woolfrey, Ann ^a,b   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF TURIN   (Italy)

Author keywords

Graft versus host disease; Human leucocyte antigen matched; Non myeloablative; Prednisone; Transplantation

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; INFANT; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 20844448047     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05458.x     Document Type: Article

References (37)

1. Boeckh, M., Gooley, T.A., Myerson, D., Cunningham, T., Schoch, G. & Bowden, R.A. (1996) Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood, 88, 4063-4071.
2. Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 99, 1071-1078.
3. Charlson, M.E., Sax, F.L., MacKenzie, C.R., Fields, S.D., Braham, R.L. & Douglas, Jr, R.G. (1986) Assessing illness severity: does clinical judgment work? Journal of Chronic Diseases, 39, 439-452.
4. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40, 373-383.
5. Colson, Y.L., Lange, J., Fowler, K. & Ildstad, S.T. (1996) Mechanism for cotolerance in nonlethally conditioned mixed chimeras: negative selection of the Vb T-cell receptor repertoire by both host and donor bone marrow-derived cells. Blood, 88, 4601-4610.
6. Cooke, K.R., Hill, G.R., Crawford, J.M., Bungard, D., Brinson, Y.S., Delmonte, Jr, J. & Ferrara, J.L. (1998) Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. Journal of Clinical Investigation, 102, 1882-1891.
7. Couriel, D.R., Saliba, R.M., Giralt, S., Khouri, I., Andersson, B., de Lima, M., Hosing, C., Anderlini, P., Donato, M., Cleary, K., Gajewski, J., Neumann, J., Ippoliti, C., Rondon, G., Cohen, A. & Champlin, R. (2004) Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biology of Blood & Marrow Transplantation, 10, 178-185.
8. Diaconescu, R., Flowers, C.R., Storer, B., Sorror, M.L., Maris, M.B., Maloney, D.G., Sandmaier, B.M. & Storb, R. (2004) Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood, 104, 1550-1558.
9. Extermann, M. (2000) Measuring comorbidity in older cancer patients (review). European Journal of Cancer, 36, 453-471.
10. Firat, S., Byhardt, R.W. & Gore, E. (2002) Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. International Journal of Radiation Oncology, Biology, Physics, 54, 357-364.
11. Fukuda, T., Boeckh, M., Carter, R.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., Martin, P.J., Storb, R.F. & Marr, K.A. (2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood, 102, 827-833.
12. Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondón, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Körbling, M., Keating, M., Kantarjian, H. & Champlin, R. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89, 4531-4536.
13. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K.G. & Thomas, E.D. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation, 18, 295-304.
14. Hill, G.R. & Ferrara, J.L. (2000) The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation [review]. Blood, 95, 2754-2759.
15. Hill, G.R., Crawford, J.M., Cooke, K.R., Brinson, Y.S., Pan, L. & Ferrara, J.L. (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood, 90, 3204-3213.
16. Ho, V.T., Zahrieh, D., Hochberg, E., Micale, E., Levin, J., Reynolds, C., Steckel, S., Cutler, C., Fisher, D.C., Lee, S.J., Alyea, E.P., Ritz, J., Soiffer, R.J. & Antin, J.H. (2004) Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood, 104, 1224-1226.
17. Hughes, W.T. (1998) Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review (review). Clinical Infectious Diseases, 27, 191-204.
18. Inouye, S.K., Peduzzi, P.N., Robison, J.T., Hughes, J.S., Horwitz, R.I. & Concato, J. (1998) Importance of functional measures in predicting mortality among older hospitalized patients. Journal of the American Medical Association, 279, 1187-1193.
19. Junghanss, C., Boeckh, M., Carter, R.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., Chauncey, T., McSweeney, P.A., Little, M.-T., Corey, L. & Storb, R. (2002) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99, 1978-1985.
20. Kalbfleisch, J.D. & Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York.
21. Koc, S., Leisenring, W., Flowers, M.E.D., Anasetti, C., Deeg, H.J., Nash, R.A., Sanders, J.E., Witherspoon, R.P., Storb, R., Appelbaum, F.R. & Martin, P.J. (2002) Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood, 100, 48-51.
22. Manilay, J.O., Pearson, D.A., Sergio, J.J., Swenson, K.G. & Sykes, M. (1998) Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation, 66, 96-102.
23. Maris, M.B., Niederwieser, D., Sandmaier, B.M., Storer, B., Stuart, M., Maloney, D., Petersdorf, E., McSweeney, P., Pulsipher, M., Woolfrey, A., Chauncey, T., Agura, E., Heimfeld, S., Slattery, J., Hegenbart, U., Anasetti, C, Blume, K. & Storb, R. (2003) HLA-matched unrelated donor hematopoietic cell transplantation after non-myeloablative conditioning for patients with hematologic malignancies. Blood, 102, 2021-2030.
24. Marr, K.A., Seidel, K., Slavin, M., Bowden, R.A., Schoch, H.G., Flowers, M.E.D., Corey, L. & Boeckh, M. (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood, 96, 2055-2061.
25. Martin, P.J. (1991) Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplantation, 8, 217-223.
26. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E.D., Georges, G.E., Grumet, F.C., Kiem, H.-P., Torok-Storb, B., Yu, C., Blume, K.G. & Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97, 3390-3400.
27. Mielcarek, M. & Storb, R. (2003) Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treatment Reviews, 29, 283-290.
28. Mielcarek, M., Martin, P.J., Leisenring, W., Flowers, M.E.D., Maloney, D.G., Sandmaier, B.M., Maris, M.B. & Storb, R. (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 102, 756-762.
29. Nash, R.A., Pepe, M.S., Storb, R., Longton, G., Pettinger, M., Anasetti, C., Appelbaum, F.R., Bowden, R., Deeg, H.J., Doney, K., Martin, P.J., Sullivan, K.M., Sanders, J. & Witherspoon, R.P. (1992) Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood, 80, 1838-1845.
30. Nestel, P.P., Price, K.S., Seemayer, T.A. & Lapp, W.S. (1992) Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor a during graft-versus-host disease. Journal of Experimental Medicine, 175, 405-413.
31. Petersdorf, E.W., Gooley, T.A., Anasetti, C., Martin, P.J., Smith, A.G., Mickelson, E.M., Woolfrey, A.E. & Hansen, J.A. (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood, 92, 3515-3520.
32. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.-G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplantation, 15, 825-828.
33. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. & Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756-763.
34. Sorror, M.L., Maris, M.B., Storer, B., Sandmaier, B.M., Diaconescu, R., Flowers, C., Maloney, D.G. & Storb, R. (2004) Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood, 104, 961-968.
35. Sullivan, K.M., Agura, E., Anasetti, C., Appelbaum, F.R., Badger, C., Bearman, S., Erickson, K., Flowers, M., Hansen, J.A., Loughran, T., Martin, P., Matthews, D., Petersdorf, E., Radich, J., Riddell, S., Rovira, D., Sanders, J., Schuening, F., Siadak, M., Storb, R. & Witherspoon, R.P. (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Seminars in Hematology, 28, 250-259.
36. Wandroo, F., Auguston, B., Cook, M., Craddock, C. & Mahendra, P. (2004) Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplantation, 34, 285-287.
37. Weiden, P.L., Flournoy, N., Thoraas, E.D., Prentice, R., Fefer, A., Buckner, C.D. & Storb, R. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New England Journal of Medicine, 300, 1068-1073.